From Mayo Clinic In your inbox Join cost-free and remain updated on study progress, overall health guidelines, existing wellness subject areas, and expertise on controlling health. Click here for an e-mail preview. Recognition of VEGF as a crucial participant in BRVO pathophysiology prompted investigation into anti-angiogenic brokers currently in use waiting for link from Social Bookmarking (3)